PledPharma

Interim report January-March 2019

Aladote® granted Orphan Drug Designation and PledOx® global Phase III program is progressing on 3 continents

January-March

- Quarterly net sales MSEK 54.9 (0.7)
- Quarterly result MSEK till 22,9 (-15,8)
- Cash and cash equivalents MSEK 258,0 (294,3)
- Cash flow from operating activities MSEK 28,0 (-15,2)
- Result per share SEK 0,5 (-0,3)
- PledPharma organized a Capital Markets Day

PledOx®

- PledPharma received MJPY 600, ca. MSEK 49, in milestone payment due to the inclusion of the first Asian patient into the global Phase III program for PledOx®
- Patients were included in Europe in the global Phase III program for PledOx® during the quarter
- PledPharma initiated an indication expansion program for PledOx in CIPN associated with taxanes
- PledPharma presented PledOx®'s global Phase III program at the Gastrointestinal (GI) Cancers Symposium, ASCO-GI

Aladote®

- Aladote® has been granted Orphan Drug Designation by FDA
- Results from the POP study support further development of Aladote® as a new treatment option for reducing the risk of acute liver injury associated with acetaminophen poisoning
- The POP study was presented at the global "58th Annual Meeting of the Society of Toxicology" in the USA

Significant events after the reporting period

- PledPharma's drug candidate Aladote® and its POP study results were recognized as one of the highlights at one of the world's largest liver conferences, European Association of the Study of the Liver International Liver Congress (EASL ILC)

	2019 Jan-Mar	2018 Jan-Mar	2018 Jan-Dec
Result after tax, SEKk	22,890	-15,811	-85,003
Cash flow, SEKk	28,161	-15,189	-79,655
Cash, SEKk	258,036	294,342	229,876
Equity ratio %	91%	96%	91%
Result per share, SEK	0.5	-0.3	-1.7
Result per share after dilution, SEK	0.5	-0.3	-1.7
Average number of employees	10	7	8

PledPharma in brief – therapies for disabling and life-threatening diseases

PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need.

The company's most advanced project **PledOx®** is being developed to prevent nerve damage associated with chemotherapy. A global phase III program is ongoing.

The drug candidate **Aladote®** is being developed to reduce the risk of acute liver injury associated with acetaminophen poisoning. A proof of principle study has been successfully completed and the design of the next study is being finalised. Aladote® has been granted Orphan Drug Designation in the US.

PledPharma (STO:PLED) is listed on Nasdaq First North. Erik Penser Bank acts Certified Adviser (www.penser.se). For further information, please see www.pledpharma.se

PledPharma

Comments from the CEO

Aladote® granted Orphan Drug Designation and PledOx® global Phase III program is progressing on 3 continents

Aladote granted Orphan Drug Designation

We are very pleased and proud that Aladote® was granted orphan drug designation (ODD) status by the FDA in March. It facilitates and enables the acceleration of Aladote® 's development to meet the significant medical needs of paracetamol poisoning. The ODD status will potentially result in shorter development time and for us also lead to lower development costs. In addition, we will receive further dedicated support from the FDA during the drug development process and seven years of market exclusivity.

Proposals for the design of the next study have been finalised together with our external advisory board and will serve as the basis for upcoming regulatory interactions.

The Phase III program for PledOx® is ongoing on all three continents

Another important step was taken in the global Phase III program, POLAR, to document PledOx® efficacy and thus become the first approved drug to prevent nerve damage (CIPN) caused by chemotherapy. In January, our Asian partner Solasia Pharma announced that the first patient had been included in Japan. As a result we received our first milestone payment of MSEK 49 from Solasia.

Patients have also been included in Europe during the quarter. With patients included in all of the POLAR program's regions (US, Europe, Asia) we are working diligently and focused to deliver top line results in the fourth quarter of 2020.

Indication expansion for PledOx®

To create further value with PledOx® an indication expansion program in CIPN associated with taxanes was initiated in the first quarter. This chemotherapeutic agent which have significant use in clinical practice do also cause CIPN. Our ambition is to create an additional opportunity to offer cancer patients a treatment that prevents side effects and improves the quality of life, in an area of great medical need similar to CIPN with oxaliplatin.

Well attended capital markets day

PledPharma's first capital markets day, which took place at the end of March, welcomed some 50 investors and analysts on site, whilst even more followed the event directly via the webcast. The capital markets day provided us with an opportunity to give more extensive information about our clinical projects and their potential, which was received positively.

Significant interest from the scientific community

Both our drug candidates have generated interest from the scientific community. The results from Aladote's® phase Ib/IIa POP study were selected for an oral presentation at one of the largest scientific conferences globally in hepatology (liver diseases), the global conference EASL ILC 2019 in Vienna. Dr James Dear, Principal Investigator, held the presentation on April 12. Furthermore, the conference organizer chose to publish the study results through a press release to the media and the international scientific community as one of the highlights of the day. The results were also presented by Dr. James Dear at a global toxicology conference in Baltimore, USA, organized by the Society of Toxicology in March.

The design of the global Phase III program POLAR for PledOx® was presented at one of the most prominent drug conferences in gastrointestinal cancer; the Global Conference on Gastrointestinal (GI) Cancer Symposium in January in San Francisco. Presenter was Prof. Per Pfeiffer from Odense University Hospital, one of the Coordinating Investigators of the POLAR studies.

Listing on the main market

The process to list our share on Nasdaq Stockholm's main market is ongoing aiming to be completed in the fourth quarter. The ambition is to create further interest from a broader investor base and reflect the maturity of our business.

Eventful year ahead

The first quarter has meant a good start to the year. With an ongoing PledOx® global Phase III program in the US, EU and Japan, the first milestone payment from our partner, an initiation of an indication expansion program in CIPN with taxanes for PledOx®, the next development phase for Aladote®, the scientific interest in our products, combined with a globally robust IP portfolio for PledOx® and Aladote® and our strong organization, I have great confidence in and look forward to our continued work.

Nicklas Westerholm, CEO
PledPharma AB, Stockholm

PledPharma

Project updates

Pledox®

Events during the quarter

PledPharma AB (publ) and Solasia Pharma K.K. reported that the first patient in Japan was included in the global Phase III program for the drug candidate PledOx®. The inclusion of the first patient represents an important milestone for both companies and entails a payment from Solasia of JPY 600 million, corresponding to approximately SEK 49 million.

Patients have also been included in Europe during the quarter, and we have had opportunities to establish relationships with several of the investigators.

We plan to have included all patients in the POLAR program to be able to present top-line results during the fourth quarter of 2020.

An indication expansion program for PledOx® in CIPN associated with taxanes was initiated in the first quarter, an area with similar unmet medical need as CIPN associated with oxaliplatin.

In January, the POLAR program was presented at the Global Conference on Gastrointestinal (GI) Cancer Symposium in San Francisco. The conference is one of the most important drug conferences globally in the field of gastrointestinal cancers, and is co-sponsored by ASCO (American Association of Clinical Oncology).

Significant events after the reporting period

There are no events to report.

About PledOx®

PledOx® is a "first in class" drug candidate developed to provide patients, that are treated adjuvantly or for metastatic colorectal cancer, prevention against the nerve damage that can occur in conjunction with chemotherapy treatment. The results from a completed Phase IIb trial (PLIANT), where patients with metastatic colorectal cancer were treated with the chemotherapy combination FOLFOX and PledOx®, indicates that the patients who received PledOx® had a lower risk than the placebo group to suffer from nerve damage during the chemotherapy. PledOx® showed 38% effect (odds ratio=0.62; p=0.16) on investigator reported sensory nerve damage, the primary endpoint, compared with the placebo group. This was not statistically significant, but a difference of this magnitude is considered clinically relevant. After completion of chemotherapy, PledOx® showed 77% effect (odds ratio=0.23; exploratory analysis: p=0.014) on patient-reported moderate and severe neuropathy compared to the placebo group. This is considered valuable for the success of the forthcoming POLAR studies, where patient-reported symptoms after completion of treatment will be the primary efficacy parameter. No apparent negative effect on the efficacy of the cancer treatment was observed. The global phase III program for PledOx® consists of two double blinded randomized placebo-controlled trials, POLAR-M and POLAR-A. POLAR-M includes 420 patients undergoing chemotherapy treatment for metastatic colorectal cancer and planned to be conducted in Asia, Europe and the US. The study compares PledOx® at doses of 2 µmol/kg and 5 µmol/kg with placebo. POLAR-A includes 280 patients undergoing adjuvant chemotherapy treatment for colorectal cancer and planned to be conducted in Asia and Europe. The study compares PledOx® at a dose of 5 µmol/kg with placebo.





Aladote®

Events during the quarter

The results from Aladote's® Phase Ib/IIa proof of principle study, POP, was presented at the global "58th Annual Meeting of the Society of Toxicology".

The US FDA granted the drug candidate Aladote® Orphan Drug Designation.

Significant events after the reporting period

The positive results from the Aladote®'s Phase Ib/IIa proof of principle-study was presented orally at the global conference EASL ILC 2019, also known as The International Liver Congress. The conference is one of the largest scientific conferences in the field of hepatology (liver diseases) globally.

About Aladote®

Aladote® is a "first-in-class" drug candidate with the potential to prevent the development of acute liver failure caused by paracetamol overdose. Aladote® has shown good efficacy in relevant preclinical models, even in the time-window when N-acetylcysteine (NAC) treatment is no longer is effective. A proof of principle study in patients with paracetamol poisoning has been successfully completed. The study results established the safety and tolerability of the combination of Aladote® and NAC. Further, the results indicate that Aladote® may reduce liver injury in this patient population. This is based on the measurement of the pre-defined exploratory biomarkers, Keratin-18 (K18) and microRNA-122 (miR-122) in patients treated with Aladote® and NAC compared to NAC alone. Proposals for the design of the next study have been finalised together with our external advisory board and will serve the basis for upcoming regulatory interactions. Aladote® has been granted Orphan Drug Designation in the US.

Paracetamol is the most used drug in the world for the treatment of fever and pain, but also one of the most overdosed drugs – intentional or unintentional. Paracetamol overdose is also one of the most common method in intentional suicide attempts. When excessive amounts of paracetamol are broken down in the liver, the harmful metabolite NAPQI is formed, which can cause acute liver failure. The current standard of care for paracetamol poisoning (NAC) is effective if the patient seeks medical care within 8 hours of ingestion. However, NAC is substantially less effective if started more than 8 hours after overdose.

Aladote is effective after the critical eight-hour threshold where NAC treatment is less effective.



Financial Information

First quarter, January - March 2019

Revenue, and results

Revenues

Revenue amounted to SEKK 54,902 (731) during the quarter and was primarily due to the milestone payment from Solasia Pharma K.K., JPY 600M (c. SEK 49M), for the inclusion of the first Asian patient into the global phase III program with PledOx®.

Expenses

Operating expenses amounted to SEKK 35,133 (19,186) for the quarter. Of these, project costs amounted to SEKK 26,239 (10,887) for the quarter. The increase is due to the global POLAR program with PledOx®. Project costs related to PledPharma amounted to SEKK 19,966.

Employee costs amounted to SEKK 5,539 (4,712) for the quarter. The increase is due to the recruitment of new employees during 2019. Also remuneration for the Board of Directors which is paid as salary according to new regulations are included. Other operating costs amounted to SEKK 2,724 (3,017) for the quarter. Depreciation amounted to SEKK 48 (0) for the quarter and is due to the implementation of IFRS 16.

Results

Operating result amounted to SEKK 19,769 (-18,455) for the quarter. Financial and related items amounted to SEKK 3,122 (2,644). Results are related to revaluation of company's FX-accounts at the end of the quarter. Results after financial items amounted to SEKK 22,890 (-15,811) for the quarter. No income tax was reported for the periods. Result per share before and after dilution amounted to SEK 0.5 (-0.3) for the quarter.

Financial position

Cash

Cash at March 31, 2019 amounted to 258,036 (294,342).

Cash flow

Cash flow from operating activities amounted to SEKK 28,015 (-15,189) for the quarter. Cash flow amounted to SEKK 28,161 (-15,189) for the quarter.

Equity and equity ratio

At March 31, 2019 equity amounted to SEKK 242,452 (287,900). Shareholders' equity per share amounted to SEK 5.0 (5.9), at the end of the period. The company's equity ratio was 91 (96) %.

Debts and receivables

Long-term liabilities amounted to SEKK 117 (0). Current liabilities amounted to SEKK 23,482 (12,148). Accounts receivables amounted to SEKK 5,441 (730). Non-current assets amounted to SEKK 283 (0). New items on the balance sheet are due to the implementation of IFRS 16.

Investments, tangible and intangible assets

During the period, investments in tangible and intangible fixed assets corresponded to SEKK 0 (0).

Share

The number of shares at March 31, 2019 were 48,666,656. PledPharma´s shares are listed on Nasdaq First North since April 7, 2011.

Warrant program

The 2018 Annual General Meeting resolved on a warrants program for employees of PledPharma of 779,500 warrants, each warrant entitles the holder to subscribe for one (1) new share in the company at a subscription price of SEK 26 per share. As of March 31, 2019, 385,000 warrants were subscribed for by employees, of which CFO and CMO subscribed for maximum allowed allocation of 100,000 each. 1,526,500 warrants had been subscribed for by employees and board members of PledPharma from the previous warrants program of which the CEO holds 500,000 warrants.

At full utilization of all warrants, the company's shares will be increased by 2 306 000 to 50 972 656.

Employees

Number of employees as of March 31, 2019 were 10 (7) persons, 3 women and 7 men.

Parent company

The parent company's revenues for the quarter amounted to SEKK 54,902 (731). Expenses for the quarter amounted to SEKK 35,139 (19,185).

The parent company's result amounted to SEKK 22,885 (-15,810) for the quarter.

Consolidated statement of comprehensive income

SEKk	2019 Jan-Mar	2018 Jan-Mar	2018 Jan-Dec
Revenue			
Sales	54,902	730	28,211
Other operating income	-	2	2
	54,902	**731**	**28,212**
Operating expenses			
Project costs	-26,239	-10,887	-83,855
Other external costs	-2,724	-3,017	-11,325
Employee benefit costs	-5,539	-4,712	-20,034
Depreciation and impairment	-48	-	-
Other operating expenses	-583	-570	-5,511
Operating result	**19,769**	**-18,455**	**-92,514**
Financial items			
Interest income and similar items	3,122	2,644	7,511
Interest expense and similar items	-1	-	-1
Result after financial net	**22,890**	**-15,811**	**-85,003**
Result before tax			
Tax	-	-	-
Result after tax	**22,890**	**-15,811**	**-85,003**
Statement of comprehensive income			
Other comprehensive income	-	-	-
Comprehensive income for the period	**22,890**	**-15,811**	**-85,003**
is entirely attributable to parent company			
Share Data			
Number of shares at the end of period	48,666,656	48,666,656	48,666,656
Average number of shares during period	48,666,656	48,666,656	48,666,656
Result per share before dilution (SEK)	0.5	-0.3	-1.7
Result per share after dilution (SEK)	0.5	-0.3	-1.7
Equity per share (SEK)	5.0	5.9	4.5
Equity per share after dilution (SEK)	5.0	5.9	4.5

PledPharma

Consolidated statement of financial position

SEKk	3/31/2019	3/31/2018	12/31/2018
ASSETS			
Non-current assets			
Tangible non-current assets	283	-	-
Financial non-current assets	-	-	-
Total non-current assets	**283**	**-**	**-**
Current assets			
Accounts receivables	5,441	730	9,444
Other receivables	586	492	624
Prepaid expenses and accrued income	1,703	4,484	2,093
	7,730	5,706	12,161
Cash and bank balance	258,036	294,342	229,876
Total current assets	**265,767**	**300,048**	**242,037**
Total assets	**266,050**	**300,048**	**242,037**

SEKk	3/31/2019	3/31/2018	12/31/2018
Equity			
Share capital	2,561	2,561	2,561
Other capital contributions	618,600	617,944	617,945
Accumulated loss including net loss	-378,709	-332,605	-401,144
Total equity	**242,452**	**287,900**	**219,362**
Long-term liabilities	**117**	**-**	**-**
Current liabilities			
Accounts payable	16,835	6,018	15,174
Other liabilities	1,557	780	1,205
Accrued expenses and deferred income	5,090	5,350	6,296
Total current liabilities	**23,482**	**12,148**	**22,675**
Total equity and liabilities	**266,050**	**300,048**	**242,037**

PledPharma

Consolidated statement of cash flows

SEKk	2019 Jan-Mar	2018 Jan-Mar	2018 Jan-Dec
OPERATING ACTIVITIES			
Result after financial net	22,890	-15,811	-85,003
Adjustments for non-cash items	48	-	-
Cash flow from operating activities before changes in working capital	**22,938**	**-15,811**	**-85,003**
Changes in short term receivables	4,431	132	-6,273
Changes in accounts payable	1,661	46	9,202
Changes in other liabilities	-1,015	445	1,765
Cash flow from operating activities	**28,015**	**-15,189**	**-80,310**
INVESTING ACTIVITIES			
Cash flow from investing activities	**-**	**-**	**-**
FINANCING ACTIVITIES			
New share/Warrants issue	200	-	655
Repayment of lease liability	-55	-	-
Cash flow from financing activities	**145**	**-**	**655**
Cash flow for the period			
Balance at beginning of period	229,876	309,531	309,531
Change in cash	28,161	-15,189	-79,655
CASH BALANCE AT THE END OF THE PERIOD	**258,036**	**294,342**	**229,876**

PledPharma

Consolidated statement of changes in equity

SEKk	Share capital	Other capital contributions	Accumulated loss incl. net result for the period	Total equity
Opening balance 20170101	**2,561**	**617,944**	**-316,794**	**303,711**
Comprehensive income for period	-	-	-15,811	-15,811
Closing balance 20180331	**2,561**	**617,944**	**-332,605**	**287,900**
Opening balance 20170101	**2,561**	**618,598**	**-401,798**	**219,362**
Transactions with shareholders	-	-	-	-
Incentive program	-	200	-	200
Comprehensive income for period	-	-	22,890	22,890
Closing balance 20171231	**2,561**	**618,798**	**-378,908**	**242,452**
Opening balance 20170101	**2,561**	**617,944**	**-316,794**	**303,711**
Transactions with shareholders	-	-	-	-
Incentive program	-	655	-	655
Comprehensive income for period	-	-	-85,003	-85,003
Closing balance 20171231	**2,561**	**618,598**	**-401,798**	**219,362**

Consolidated key ratios

The key ratios below are useful to those who read the financial statements and a complement to other performance targets in evaluating strategic investment implementation and the Group's ability to achieve financial goals and commitments.

SEKk	2019 Jan-Mar	2018 Jan-Mar	2018 Jan-Dec
Equity	242,452	287,900	219,362
Equity ratio %	91%	96%	91%
Return on equity %	neg.	neg.	neg.
Number of shares at the end of the period	48,666,656	48,666,656	48,666,656
Number of shares at the end of the period after dilution	48,666,656	48,666,656	48,666,656
Average number of shares under the period	48,666,656	48,666,656	48,666,656
Average number of shares under the period after dilution	48,666,656	48,666,656	48,666,656
Share Data			
Result per share	0.5	-0.3	-1.7
Result per share after dilution	0.5	-0.3	-1.7
Cash flow from operating activities	0.6	-0.3	-1.7
Equity per share	5.0	5.9	4.5
Equity per share after dilution	5.0	5.9	4.5
Dividend	-	-	-
Average number of employees	10	7	8

PledPharma

Key ratios definitions

Ratios that have been calculated according to IFRS

Earnings per share Net income divided by average number of shares before dilution

Number of shares at end of period The number of outstanding shares before dilution at the end of the period

Number of shares after dilution The number of issued shares after dilution effect of potential shares at end of period

Average number of shares during the period Average number of outstanding shares before dilution for the period

Average number of shares during the period after dilution Average number of issued shares after dilution effect of potential shares

Number of employees (average) The average number of employees at the end of each period

Ratios that have not been calculated in accordance with IFRS

Equity ratio, % The company defines the ratio as follows; The period's closing equity divided by the period's closing balance sheet. The company uses the alternate ratio Equity as it shows the proportion of total assets represented by shareholders' equity and has been included to allow investors to assess the company's capital structure.

Return on equity, % The company defines the ratio as follows; Net income divided by shareholders' equity. The company uses the alternate key figure Return on equity, % because the company believes that the key ratio gives investors a better understanding of the return generated on the total capital that the shareholders have invested in the Company.

Cash flow from operations per share The company defines the ratio as follows; Cash flow from operating activities divided by the number of shares outstanding at the end of the period. The company uses the alternate key figure Cash flow from operations per share because the Company believes that the key ratio gives investors a better understanding of the company's cash flow in relation to its number of shares adjusted for changes in the number of shares outstanding during the period.

Equity per share The company defines the ratio as follows; Equity divided by number of shares outstanding at the end of the period. The company uses the alternate key ratio equity per share because the Company believes that the key ratio gives investors a better understanding of the historical return per share adjusted for changes in the number of shares outstanding during the period.

PledPharma

Parent company - income statement

SEKk	2019 Jan-Mar	2018 Jan-Mar	2018 Jan-Dec
Revenue			
Sales	54,902	730	28,211
Other operating income	-	2	2
	54,902	**731**	**28,212**
Operating expenses			
Project costs	-26,239	-10,887	-83,855
Other external costs	-2,778	-3,016	-11,324
Employee benefit costs	-5,539	-4,712	-20,034
Depreciation and impairment	-	-	-
Other operating expenses	-583	-570	-5,511
Operating result	**19,763**	**-18,454**	**-92,513**
Financial items			
Interest income and similar items	3,122	2,644	7,510
Interest expense and similar items	-	-	-1
Result after financial net	**22,885**	**-15,810**	**-85,003**
Result before tax			
Group contribution received	-	-	654
Tax	-	-	-
Result after tax	**22,885**	**-15,810**	**-84,350**
Statement of comprehensive income			
Other comprehensive income	-	-	-
Comprehensive income for the period	**22,885**	**-15,810**	**-84,350**

PledPharma

Parent company - balance sheet

SEKk	3/31/2019	3/31/2018	12/31/2018
ASSETS			
Non-current assets			
Tangible non-current assets	-	-	-
Financial non-current assets	50	50	50
Total non-current assets	**50**	**50**	**50**
Current assets			
Receivables from group companies	2,686	2,083	2,686
Accounts receivables	5,441	730	9,444
Other receivables	586	492	624
Prepaid expenses and accrued income	1,703	4,484	2,093
	10,417	7,789	14,848
Cash and bank balance	255,101	292,260	227,139
Total current assets	**265,517**	**300,049**	**241,987**
Total assets	**265,567**	**300,099**	**242,037**

SEKk	3/31/2019	3/31/2018	12/31/2018
Equity			
Restricted Equity			
Share capital	2,561	2,561	2,561
Non-restricted equity			
Share premium reserve	618,599	617,943	617,944
Retained earnings	-401,799	-316,794	-316,794
Net profit for the year	22,885	-15,810	-84,350
Total equity	**242,247**	**287,901**	**219,362**
Long-term liabilities			
Current liabilities			
Liabilities to group company	-	50	-
Accounts payable	16,835	6,018	15,174
Other liabilities	1,396	780	1,205
Accrued expenses and deferred income	5,090	5,350	6,296
Total current liabilities	**23,321**	**12,198**	**22,675**
Total equity and liabilities	**265,567**	**300,099**	**242,037**

Notes

Note 1 - Accounting principles

PledPharma applies International Financial Reporting Standards (IFRS) as adopted by the EU. This report is prepared in accordance with IAS 34 Interim Financial Reporting and the Annual Accounts Act. Applied accounting principles and calculation methods are the same as in the latest annual report for 2018. Except that the company has shifted to account according to IFRS 16.

Parent company

The parent company PledPharma AB (Publ) prepares financial reports in accordance with the Swedish Financial Reporting Board's recommendation RFR 2 Accounting for Legal Entities and the Swedish Annual Accounts Act. All leases are reported operationally in the Parent Company.

New standards, amendments and interpretations applied by the Group as of January 1, 2019

IFRS 16 has entered into force on January 1, 2019. IFRS 16 replaces IAS 17 Lease Agreement, with new accounting requirements for lessee. All leases, except short-term and minor leasing contracts, shall be reported as an asset with right of use and as a corresponding liability in the leaseholder's balance sheet. The standard is expected to provisionally mean that most of the leases reported in these financial statements as operating leases will be reported as assets and liabilities in the financial statement. This will also cause the cost of these to be reported broken down into interest expense and depreciation. PledPharma applies the simplified transition model. Leasing contracts of minor value will henceforth be accounted as operating leases and reported in the income statement. Company's leasing portfolio consists of five agreements which includes operating leases of office, office equipment and cars. At the entry into 2019 one of the company's rental agreements had a duration of less than 12 months, two contracts related to office equipments was regarded to be of minor value. These agreements fall into the exception of short term leasing contracts and minor leasing contracts.

SEKk	
Leasing agreements according to Note 20, annual report	1,109
Deduction for short-term leases	-907
Discounted according to Group's borrowing interest rate of 2%	-7
Adjustments future lease payments	137
Presented liability, 2019-01-01	332

Note 2 – Additional information

Other information in accordance with IAS 34.16A are found on pages before the income statement and statement of comprehensive income. Information on earnings, cash flow and financial position, see page 5. For events after the period, see page 1.

Note 3 – Financial assets and liabilities

SEKk	Hold to collect	Financial debts	Total
	Amortised cost	Amortised cost	
Other long-term securities	-	-	-
Other long-term receivables	-	-	-
Accounts receivable	730	-	730
Cash	294,342	-	294,342
Total assets	**295,072**	-	**295,072**
Valued financial assets			
Other long-term liabilities			
Conditional acquistiion difference			
Other short-term liabilities			
Financial assets that are not			
Other long-term liabilities	-	-	-
Other short-term interest bearing	-	-	-
Accounts payable	-	6,018	6,018
Other liabilities	-	-	-
Total liabilities	**-**	**6,018**	**6,018**

Note 4 – Related parties transactions

There are none transactions to be reported with related parties.

Other information

Next reports
Interim report Jan – Jun 2019, Aug 21, 2019
Interim report Jan – Sep 2019, Oct 23, 2019
Year-end report Jan – Dec 2019, Feb 18, 2020

This report, and further information is available on the website, www.pledpharma.se
This report has not been reviewed by the company's auditor. This is a translation of the Swedish interim report.

For further information, please contact:
Nicklas Westerholm, vd
Phone:+46 (0)73-354 20 62
E-mail: nicklas.westerholm@pledpharma.se

Yilmaz Mahshid, CFO
T Phone:+46 (0)72-231 68 00
E-mail: yilmaz.mahshid@pledpharma.se

This information is such information as PledPharma AB (publ) is obliged to disclose in accordance with EU market abuse regulation and the Securities Markets Act. The information was submitted, through the above contact persons, for publication on May 6, 2019 at 8.00 am (CET).

PledPharma AB (publ)
Grev Turegatan 11c, 114 46 Stockholm
Org.nr. 556706-6724
Phone: +46(0)8-679 72 10
www.pledpharma.se

Certified Adviser
The company´s Certified Advisor is Erik Penser Bank (phone +46 8 463 80 00).

Analysts who follow PledPharma
Redeye, Klas Palin.
Carnegie, Ulrik Trattner.

Certification

This report provides a true and fair overview of the company's business activities, financial position, and results of operations, and describes significant risks and uncertainties to which the company is exposed.

Stockholm, May 6, 2019

Håkan Åström	Marie Ekström Trägårdh
Chairman of the board	Board member
Sten Nilsson	Gunilla Osswald
Board member	Board member
Elisabeth Svanberg	Nicklas Westerholm
Board member	*CEO*